Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 61

Results For "disease"

3231 News Found

Pfizer drug candidate shows strong results in tough breast cancer study
Clinical Trials | March 19, 2026

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged


IIT Roorkee unveils cutting-edge molecular medicine facility
R&D | March 19, 2026

IIT Roorkee unveils cutting-edge molecular medicine facility

The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics


Zydus and Torrent Pharma to co-market Semaglutide injection in India
News | March 19, 2026

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device


Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
News | March 18, 2026

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025


Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
Drug Approval | March 18, 2026

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options


Zydus, Lupin join forces to expand access to semaglutide in India
News | March 18, 2026

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus


EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers
News | March 17, 2026

EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers

AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible


Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema
Clinical Trials | March 17, 2026

Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema

The company announced positive topline data from the Phase 3 ADorable-1 trial


Merck doubles down on cardio-pulmonary breakthroughs
News | March 17, 2026

Merck doubles down on cardio-pulmonary breakthroughs

At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure